The Trump administration will not renew a program that has subsidized prescription drug costs for Medicare beneficiaries, a move that is expected to lead to higher premiums for some seniors starting in 2027. The program, known as the Senior Savings Model, was designed to hold down costs for Medicare Part D plans.
This initiative, launched in 2019, aimed to reduce out-of-pocket expenses for individuals enrolled in Medicare prescription drug plans. By capping beneficiaries' monthly out-of-pocket costs at $35, the program sought to make medications more affordable. The decision not to renew the program means that the cost-lowering benefits will cease at the end of 2026.
While the administration has not provided a detailed explanation for the decision, policy analysts suggest it may be part of a broader effort to reduce federal spending or to allow market forces to dictate drug pricing. The discontinuation of the subsidy is anticipated to affect a significant number of Medicare beneficiaries who have benefited from the program's cost-saving measures.